Scarica l'app Stockscreener
77.38
0.43%
0.5403
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Yahoo Finance
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP research & development sells $265,370 in stock - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $265,370.00 in Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative - webull.com
Cytokinetics (NASDAQ:CYTK) Raised to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright reiterates Cytokinetics stock rating on patent suit By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Cytokinetics stock rating on patent suit - Investing.com
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript - AOL.com
Cytokinetics files patent lawsuit against Bristol-Myers Squibb over heart drug - The Business Journals
Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients - Stock Titan
CYTK Maintained by Barclays -- Price Target Raised to $110 - GuruFocus
CYTK Looks 60.3% Undervalued on GF Value™ Despite Legal Dispute - GuruFocus
CYTK Maintained by JP Morgan -- Price Target Raised to $103 - GuruFocus
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $103.00 - MarketBeat
Cytokinetics sues Bristol-Myers in patent case (CYTK:NASDAQ) - Seeking Alpha
Form 8K Cytokinetics Inc For: 13 August By Investing.com - Investing.com Nigeria
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb - Investing.com South Africa
Cytokinetics Initiates Legal Action Challenging Patent on MYQORZO (Aficamten) - Kalkine Media
PD Small-Cap Value Index Portfolio's Cytokinetics Inc(CYTK) Holding History - GuruFocus
Barclays raises Cytokinetics stock price target on strong Myqorzo sales - Investing.com
Barclays raises Cytokinetics stock price target on strong Myqorzo sales By Investing.com - Investing.com Australia
Cytokinetics, Incorporated $CYTK Shares Purchased by Tema ETFs LLC - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics president & CEO Robert Blum sells $575,700 in shares By Investing.com - Investing.com UK
Cytokinetics Insider Sold Shares Worth $575,700, According to a Recent SEC Filing - moomoo.com
HC Wainwright Raises Earnings Estimates for Cytokinetics - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
Cytokinetics president & CEO Robert Blum sells $575,700 in shares - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $575,700.00 in Stock - MarketBeat
Cytokinetics, Incorporated Revenue Breakdown – NASDAQ:CYTK - TradingView
CYTOKINETICS, INCORPORATED : LEERINK PARTNERS RAISES TARGET PRICE TO $103 FROM $100 - Bitget
CYTOKINETICS, INCORPORATED : TRUIST SECURITIES RAISES TARGET PRICE TO $112 FROM $106 - Bitget
Truist Adjusts Price Target on Cytokinetics to $112 From $106, Maintains Buy Rating - marketscreener.com
1.34%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):